drugset

drugset / Trial / NCT07647133

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease

NCT07647133 ↗

Phase 2 Not yet recruiting 249 enrolled Shenzhen Salubris Pharmaceuticals Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of SAL0140 in patients with chronic kidney disease (CKD).

Timeline

Start: 2026-06-15
Primary completion: 2027-10-08
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SAL0140	Unknown	—	—

Indications